Loading clinical trials...
Loading clinical trials...
A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Conditions
Interventions
Recombinant Anti-CD19m-CD3 Antibody Injection
Start Date
September 15, 2019
Primary Completion Date
September 30, 2021
Completion Date
January 27, 2022
Last Updated
August 14, 2019
Lead Sponsor
EVIVE Biotechnology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions